Darovasertib
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Jan 25, 2026 → Mar 1, 2031
NCT ID
NCT07015190About Darovasertib
Darovasertib is a phase 3 stage product being developed by IDEAYA Biosciences for Uveal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07015190. Target conditions include Uveal Melanoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07015190 | Phase 3 | Recruiting |
| NCT05907954 | Phase 2 | Active |
Competing Products
20 competing products in Uveal Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Entinostat | Merck | Phase 2 | 52 |
| Pembrolizumab + Olaparib | Merck | Phase 2 | 52 |
| Pembrolizumab 25 MG/1 ML Intravenous Solution | Merck | Phase 2 | 52 |
| AEB071 | Novartis | Phase 1 | 33 |
| LXS196 + LXS196 and HDM201 | Novartis | Phase 1 | 33 |
| DYP688 | Novartis | Phase 1/2 | 41 |
| RAD001 (Everolimus) and Pasireotide (SOM230) LAR | Novartis | Phase 2 | 52 |
| ranibizumab + triamcinolone acetonide | Novartis | Phase 2/3 | 65 |
| Crizotinib | Pfizer | Phase 2 | 51 |
| Dacarbazine + Sunitinib | Pfizer | Phase 2 | 51 |
| AEB071 + MEK162 | Pfizer | Phase 1/2 | 40 |
| Binimetinib + Belinostat | Pfizer | Phase 2 | 51 |
| Ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| ZIV-Aflibercept + Cemiplimab | Sanofi | Phase 2 | 51 |
| Ziv-Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
| XmAb®23104 + Yervoy® (ipilimumab) | ICON plc. | Phase 1 | 30 |